TGFB1 and neoplasm: Recently, we demonstrated that the activation of FCs by dual-administered TLR agonists is more effective in comparison to those single activated or un-activated FCs, however, immune-suppressive cytokines such as TGF-β1 secreted from whole tumor cells inhibited the activation of FCs [42].